Welcome to our dedicated page for Oncolytics Biotech news (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech stock.
Oncolytics Biotech, Inc. (Nasdaq: ONCY) is a clinical-stage biotechnology company whose news flow centers on the development of pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Company updates frequently highlight clinical data in metastatic pancreatic cancer, metastatic breast cancer, and gastrointestinal tumors such as anal and colorectal cancers, where pelareorep is being evaluated in combination with chemotherapy and checkpoint inhibitors.
News releases from Oncolytics often cover clinical trial milestones, including results from the GOBLET study in squamous cell anal carcinoma and colorectal cancer, as well as alignment with the U.S. Food and Drug Administration on pivotal trial designs in first-line metastatic pancreatic ductal adenocarcinoma. Investors can also expect announcements about planned registration-directed studies, accelerated approval strategies in indications with no FDA-approved therapies, and translational findings such as tumor-specific T-cell responses in KRAS-mutant metastatic colorectal cancer.
Oncolytics’ news also addresses corporate and regulatory developments, including its proposal to change its jurisdiction of incorporation from Alberta, Canada, to the State of Nevada, its transition to domestic issuer status under SEC rules, and capital markets activities such as at-the-market equity programs. Additional updates describe expansions of the company’s Gastrointestinal Tumor Scientific Advisory Board and appointments of senior leaders in strategy, operations, and biostatistics to support late-stage clinical execution.
This ONCY news page aggregates these press releases and related coverage so readers can follow key developments in pelareorep’s clinical progress, regulatory interactions, intellectual property initiatives, and corporate strategy. It is a useful resource for tracking how new data, advisory board input, and structural changes may influence the company’s oncology pipeline over time.
Oncolytics Biotech announced promising preclinical data highlighting the synergistic effects of pelareorep combined with radiotherapy. Presented at The International Conference on Immunotherapy Radiotherapy Combinations in Paris, the study demonstrated a significant increase in anti-cancer CD8+ T cells and improved survival rates in murine models. The pelareorep-radiotherapy combination outperformed single-agent therapies, indicating its potential for broader application across multiple cancer types. These findings advocate for further research into pelareorep as an effective cancer treatment.
Oncolytics Biotech reported significant progress in its clinical trials and financial health for Q2 2021. The AWARE-1 trial achieved its primary endpoint, showing that pelareorep synergizes with checkpoint inhibitors, enhancing survival metrics in breast cancer. Additionally, proof-of-concept data in metastatic pancreatic cancer indicates broad applicability across tumor types. The company maintains a strong financial position with $50.8 million in cash, supporting ongoing trials and strategic partnerships.
Oncolytics Biotech (NASDAQ: ONCY) announces its participation in the Canaccord Genuity 41st Annual Growth Conference, scheduled for August 10-12, 2021. Dr. Matt Coffey, CEO, will present on August 12 at 1:30 p.m. EDT. The event includes one-on-one investor meetings, and a live webcast will be available on Oncolytics' Investor Relations page, archived for 90 days. The company develops pelareorep, an immunotherapeutic agent aimed at treating various cancers by inducing immune responses. For more information, visit their website.
Oncolytics Biotech (NASDAQ: ONCY) will hold a conference call on August 6, 2021, at 8:00 a.m. ET to discuss the second quarter financial results and corporate updates. The call will be accessible via a toll-free number and will also be available through a webcast for three months. The biotechnology company is focused on developing pelareorep, an immunotherapeutic agent that induces anti-cancer immune responses. This agent is currently in clinical trials for various cancers, including a registration study in metastatic breast cancer.
Oncolytics Biotech Inc. (NASDAQ: ONCY) announced it will present at the Ladenburg Thalmann Healthcare Conference on July 14, 2021, at 4:30 PM Eastern Daylight Time. Dr. Matt Coffey, President & CEO, will lead the presentation. A live webcast will be available on the company's Investor Relations page and archived for 90 days. Oncolytics is developing pelareorep, an immunotherapeutic agent aimed at treating various cancers by inducing immune responses. The company is also engaging in one-on-one investor meetings during the conference.
Oncolytics Biotech (NASDAQ: ONCY) announced a promising clinical proof-of-concept for its pelareorep-checkpoint inhibitor combination therapy in pancreatic cancer. The phase 2 trial, featuring pembrolizumab (KEYTRUDA), showed a 42% disease control rate among patients who had progressed after first-line treatment. The results will be presented at the ASCO Annual Meeting in June 2021. Key findings highlight enhanced T cell activation and well-tolerated treatment. Oncolytics plans to further develop this therapy in collaboration with Roche through the GOBLET study.
Oncolytics Biotech Inc. (NASDAQ: ONCY) will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 5:25 pm ET. Dr. Matt Coffey, President & CEO, will present, with a live webcast available on the company’s Investor Relations page. The conference runs from May 18-20, 2021, featuring one-on-one investor meetings. Oncolytics is developing pelareorep, an immuno-oncolytic virus aimed at treating various cancers, including in combination with checkpoint inhibitors. For more details, visit Oncolytics' website.
Oncolytics Biotech announced the voting results from its Annual General Meeting held on May 7, 2021, with 41.41% of shares represented. All seven nominated directors were elected, receiving significant support: Deborah M. Brown (82.43%), Matthew C. Coffey (79.86%), and others exceeding 79% approval. Shareholders also approved resolutions relating to the number of directors and auditor appointments. Oncolytics continues to develop pelareorep for cancer treatment, highlighting ongoing clinical trials and strategic plans for a phase 3 registration study in metastatic breast cancer.
Oncolytics Biotech (NASDAQ: ONCY) reported solid clinical progress and financial results for Q1 2021. Key highlights include the successful achievement of primary endpoints in the AWARE-1 trial and strong preclinical data supporting pelareorep's synergy with various immunotherapeutic agents, including CAR T therapies. With over $50 million in cash, the company expects a cash runway through Q4 2022. The Phase 2 BRACELET-1 trial remains on track for full enrollment in Q4 2021, supporting the potential for enhanced breast cancer treatments.
Oncolytics Biotech (NASDAQ: ONCY) announces its upcoming 2021 Annual General Meeting, scheduled for May 7, 2021, at 12:00 p.m. ET. The meeting will be held virtually to ensure the safety of employees and shareholders. Shareholders are encouraged to vote by proxy before the May 5 deadline. Following the meeting, Oncolytics will provide a corporate update and discuss its first quarter 2021 financial results. The event will be accessible online. For detailed instructions on attending and voting, participants can refer to the company's Management Information Circular.